CARMAT |
Market Closed -
Other stock markets
|
After market 03:24:26 pm | |||
| 4.07 EUR | +14.33% |
|
4.073 | +0.07% |
| May. 06 | Carmat: progress in ongoing clinical study | CF |
| May. 06 | CARMAT Continues to Build on Its Momentum in the EFICAS Study | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.56
EUR
Average target price
14.22
EUR
Spread / Average Target
+299.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.25% | 95.1M | |
| +9.76% | 127B | |
| -6.58% | 10.91B | |
| +2.70% | 9.24B | |
| -20.23% | 7.44B | |
| +35.01% | 5.44B | |
| +8.23% | 3.44B | |
| -9.05% | 2.87B | |
| -5.57% | 2.25B | |
| -0.60% | 2.23B |
- Stock Market
- Equities
- ALCAR Stock
- News CARMAT
- France’s Carmat Secures EUR17 Million via Capital Raise; Shares Fall